Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PZ703b TFA, a Bcl-xl PROTAC degradation agent, promotes apoptosis and halts bladder cancer cell proliferation, making it a pertinent investigative compound for related oncological studies [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | PZ703b TFA, a Bcl-xl PROTAC degradation agent, promotes apoptosis and halts bladder cancer cell proliferation, making it a pertinent investigative compound for related oncological studies [1] [2]. |
In vitro | PZ703b (0-1 μM, 24 h) TFA synergistically enhances the anti-proliferative effects of Mivebresib against bladder cancer cells in a dose-responsive manner while also inducing apoptosis through the mitochondrial pathway [1]. Additionally, PZ703b (0-1 μM, 48 h) TFA demonstrates potent inhibition of MOLT-4 and RS4;11 cell lines, with respective IC50 values of 15.9 and 11.3 nM [2]. At a concentration of 10 nM over 48 hours, PZ703b TFA prompts considerable and lasting BCL-XL degradation, culminating in caspase-3 mediated apoptosis in MOLT-4 cells [2]. |
Molecular Weight | 1714.46 |
Formula | C82H103ClF6N10O13S4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PZ703b TFA PROTAC PROTACs inhibitor inhibit